Ipsen Pharma Aggregatedpresentationbydayandbymarket Purchases of own shares from June 17th to 21th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 17/06/2024 FR0010259150 6 600 120,3723 XPAR IPSEN 549300M6SGDPB4Z94P11 17/06/2024 FR0010259150 2 400 120,4326 CEUX IPSEN 549300M6SGDPB4Z94P11 17/06/2024 FR0010259150 515 120,4006 TQEX IPSEN 549300M6SGDPB4Z94P11 17/06/2024 FR0010259150 485 120,4344 AQEU IPSEN 549300M6SGDPB4Z94P11 18/06/2024 FR0010259150 7 537 119,3154 XPAR IPSEN 549300M6SGDPB4Z94P11 18/06/2024 FR0010259150 2 463 119,0330 CEUX IPSEN 549300M6SGDPB4Z94P11 19/06/2024 FR0010259150 4 000 117,7254 XPAR IPSEN 549300M6SGDPB4Z94P11 20/06/2024 FR0010259150 5 743 117,1677 XPAR IPSEN 549300M6SGDPB4Z94P11 20/06/2024 FR0010259150 1 957 117,1431 CEUX IPSEN 549300M6SGDPB4Z94P11 20/06/2024 FR0010259150 100 117,0000 TQEX IPSEN 549300M6SGDPB4Z94P11 20/06/2024 FR0010259150 200 116,9350 AQEU IPSEN 549300M6SGDPB4Z94P11 21/06/2024 FR0010259150 2 737 115,3567 XPAR IPSEN 549300M6SGDPB4Z94P11 21/06/2024 FR0010259150 1 263 115,0259 CEUX TOTAL 36 000 118,4864 Attachment EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 25_2024
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...